Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Mar;44(3):336-42.
doi: 10.1016/j.jsat.2012.08.016. Epub 2012 Sep 26.

Predictors of outcome after short-term stabilization with buprenorphine

Maureen Hillhouse  1 , Catherine P Canamar, Walter Ling
Affiliations
Randomized Controlled Trial

Predictors of outcome after short-term stabilization with buprenorphine

Maureen Hillhouse et al. J Subst Abuse Treat. 2013 Mar.

Abstract

Using buprenorphine as a medication to treat opioid dependence is becoming more prevalent as illicit opiate use increases. Identifying the characteristics of opiate dependent individuals best suited to benefit from buprenorphine would improve guidelines for its administration. This study evaluates baseline and treatment participation variables for predicting positive response to short-term stabilization with buprenorphine. Data include demographic, drug use, and other variables collected from participants undergoing stabilization over a 4-week period before being tapered off buprenorphine in a short-term detoxification process. Outcome variables include opioid use and retention. Logistic regression results indicate several characteristics associated with opioid use at the end of the stabilization period. These include being older, having no criminal history, and less opiate use. Criminal activity and opioid use in the last 30 days were significantly associated with shorter treatment stays. The benefits of identifying individual characteristics that may predict treatment response are discussed.

Trial registration: ClinicalTrials.gov NCT00078117.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement: No author contributing to this manuscript reports a conflict of interest, financial or otherwise.

Figures

Figure 1
Figure 1
Retention (number of weeks until drop-out) by Predictor Variables.
See this image and copyright information in PMC

References

    1. Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug and Alcohol Dependence. 2000;58:143–52. - PubMed
    1. Amato L, Davoli M, Minozzi S, Ali R, Ferri M. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev. 2005:CD003409. - PubMed
    1. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri MM, Mayet S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2008:CD005031. - PubMed
    1. Awgu E, Magura S, Rosenblum A. Heroin-dependent inmates’ experiences with buprenorphine orm ethadone maintenance. Journal of Psychoactive Drugs. 2010;42:339–346. - PMC - PubMed
    1. Berman AH, Kallmen H, Barredal E, Lindqvist P. Hopeless patients? A study of illicit opiate users who drop out from in-patient detoxification. Journal of Substance Use. 2007;13:121–130.

Publication types

Associated data